AKTX · XBRL financial data
Akari Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (AKTX's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 9 | 9 | 10 | 5 | 7 | 3 |
| Selling, general and administrative | 9 | 8 | 14 | 11 | 10 | 9 |
| Total operating expenses | 18 | 17 | 23 | 17 | 22 | 17 |
| Operating income (loss) | (18) | (17) | (23) | (17) | (22) | (17) |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | — | — | — | — | 0 | 0 |
| Other income (expense) | — | — | (0) | (0) | (0) | — |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | (1) |
| Net income (loss) | (17) | (17) | (18) | (10) | (20) | (17) |
| Earnings per share, basic USD per share | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted average shares, basic millions of shares | 3,159 | 4,292 | 6,243 | 9,789 | 23,888 | 67,328 |
| Weighted average shares, diluted millions of shares | 3,159 | 4,292 | 6,243 | 9,789 | 23,888 | 67,328 |
Balance sheet
CSVFiscal years (AKTX's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 14 | 9 | 13 | 4 | 3 | 0 |
| Prepaid and other current assets | 1 | — | — | — | — | — |
| Total current assets | 15 | 12 | 14 | 4 | 3 | 5 |
| Property and equipment, net | 0 | 0 | 0 | — | — | — |
| Goodwill | — | — | — | — | 8 | 8 |
| Total assets | 15 | 12 | 14 | 4 | 51 | 48 |
| Accounts payable | 3 | 2 | 1 | 2 | 12 | 9 |
| Accrued liabilities | 2 | 3 | 3 | 2 | 3 | 2 |
| Total current liabilities | — | — | — | 5 | 20 | 12 |
| Total liabilities | 5 | 6 | 12 | 5 | 28 | 20 |
| Accumulated deficit | (182) | (200) | (217) | (227) | (247) | (265) |
| Total stockholders' equity | 9 | 6 | 2 | (0) | 22 | 28 |
| Total liabilities and equity | 15 | 12 | 14 | 4 | 51 | 48 |
| Common shares outstanding (cover page) millions of shares | 3,847 | 4,760 | 7,445 | 15,847 | 57,753 | 91,567 |
Cash flows
CSVFiscal years (AKTX's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (17) | (17) | (18) | (10) | (20) | (17) |
| Stock-based compensation | 0 | 0 | 1 | 1 | 2 | 3 |
| Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | — |
| Net cash from operating activities | (17) | (19) | (22) | (16) | (13) | (11) |
| Net cash from investing activities | — | — | — | — | 0 | — |
| Proceeds from issuing common stock | 25 | 14 | 25 | 7 | 12 | 11 |
| Net cash from financing activities | 25 | 14 | 25 | 7 | 11 | 13 |
| Net change in cash | 8 | (5) | 4 | (9) | (1) | 3 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Akari Therapeutics | 7.7 | not reported | (3.1)* | 155.8B | 2.5 quarters | 10-QJun 30, 2026 |
| X4 Pharmaceuticals | 186 | 2.9 | (20)* | 102.1M | 9.2 quarters | 10-QSep 30, 2026 |
| ProPhase Labs | 0 | 1 | (0.1)* | 15.6M | 0.3 quarters | 10-QJun 30, 2026 |
| Pluri | 3.5 | 0.3* | (4.4)* | 12.3M | 0.8 quarters | 10-KJun 30, 2026 |
| CalciMedica | 19 | not reported | (4.6)* | 34.1M | 4.0 quarters | 10-QJun 30, 2026 |
| Edesa Biotech | 10 | not reported | (3.1)* | 9.6M | 3.3 quarters | 10-QJun 30, 2026 |
| GeoVax Labs | 3.1 | not reported | (3.7)* | 7.4M | 0.9 quarters | 10-QJun 30, 2026 |
| Lipocine | 5 | 0.2 | (3)* | 8.2M | 7.7 quarters | 10-QJun 30, 2026 |
| Earth Science Tech | 0.6 | 9 | 0.7 | 287.6M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.